877606-63-8

877606-63-8 structure

Name: Afacifenacin
Chemical Name: (4S)-4-phenyl-3-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-1,4-dihydroquinazolin-2-one
CAS Number: 877606-63-8
Molecular Formula: C₂₇H₂₆F₃N₃O₂
Molecular Weight: 481.50900
Catalog: Signaling Pathways GPCR/G Protein mAChR
Create Date: 2017-03-25 18:55:39
Modify Date: 2025-08-25 09:25:31
Afacifenacin (SMP-986) is a potent and orally active muscarinic receptor antagonist. Afacifenacin inhibits the bladder afferent pathway through the sodium-channel blockade, increasing volume, and reducing the frequency of urination and incontinence. Afacifenacin has the potential for the research of overactive bladder (OAB)[1][2].

Name	(4S)-4-phenyl-3-[1-[[3-(trifluoromethoxy)phenyl]methyl]piperidin-4-yl]-1,4-dihydroquinazolin-2-one
Synonyms	UNII-XQU62QZ74P Afacifenacin

Description	Afacifenacin (SMP-986) is a potent and orally active muscarinic receptor antagonist. Afacifenacin inhibits the bladder afferent pathway through the sodium-channel blockade, increasing volume, and reducing the frequency of urination and incontinence. Afacifenacin has the potential for the research of overactive bladder (OAB)[1][2].
Related Catalog	Signaling Pathways >> Neuronal Signaling >> mAChR Signaling Pathways >> GPCR/G Protein >> mAChR Research Areas >> Metabolic Disease
In Vivo	Afacifenacin (0.3, 1, 3 mg/kg; Intragastric administration) 显着增加脑梗死大鼠的膀胱容量和降低排尿压力 (MP)[2]。 Animal Model: Male Sprague-Dawley rats (cerebral infarction model)[2] Dosage: 0.3, 1, 3 mg/kg Administration: Intragastric administration Result: Significantly increased bladder capaticy and reduced micturition pressure (MP) without affecting residual urinary volume (RUV).
References	[1]. Yeo EK, et al. New therapies in the treatment of overactive bladder. Expert Opin Emerg Drugs. 2013 Sep;18(3):319-37. [2]. Natsuko Goto, et al. Dual inhibition of Na+-channel and muscarinic receptor by SMP-986 efficiently improved voiding function compared to anti-muscarinic agents in two conscious rat models of detrusor overactivity. The Journal of Urology. 2008, 179, 129.